The goal of this study is to learn whether semaglutide (treatment for type 2 diabetes and obesity) can improve signs and symptoms of hypogonadism in men with type 2 diabetes, obesity and hypogonadism (a condition when levels of testosterone are decreased). The main questions the study aims to answer are: * Does semaglutide improve the quality of sperm? * Does semaglutide improve symptoms of hypogonadism as well as testosterone replacement? The researchers will compare semaglutide to testosterone replacement to see which drug better treats symptoms of hypogonadism. * The participants will receive testosterone replacement therapy (intramuscular injection every 10-12 weeks) or magnitude (subcutaneous injection once a week). * The treatment will last 24 weeks. * The participants will visit the clinic at the start and the end of the study. At the visit, the researchers will measure body weight and take a few blood samples. The participants will also be asked to complete several questionnaires and collect a sperm sample. The participants are free to terminate their participation in the study at any time without giving a reason.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Change in semen volume from baseline and between the treatment arms
Timeframe: Baseline and 24 weeks
Change in sperm concentration from baseline and between the treatment arms
Timeframe: Baseline and 24 weeks
Change in total motility of sperm from baseline and between the treatment arms
Timeframe: Baseline and 24 weeks
Change in normal sperm forms from baseline and between the treatment arms
Timeframe: Baseline and 24 weeks
Change in total number of sperm from baseline and between the treatment arms
Timeframe: Baseline and 24 weeks